JP2021530437A - 改良されたｆｖｉｉｉ融合タンパク質及びその応用 - Google Patents

改良されたｆｖｉｉｉ融合タンパク質及びその応用 Download PDF

Info

Publication number
JP2021530437A
JP2021530437A JP2020564649A JP2020564649A JP2021530437A JP 2021530437 A JP2021530437 A JP 2021530437A JP 2020564649 A JP2020564649 A JP 2020564649A JP 2020564649 A JP2020564649 A JP 2020564649A JP 2021530437 A JP2021530437 A JP 2021530437A
Authority
JP
Japan
Prior art keywords
kda
seq
fusion protein
group
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564649A
Other languages
English (en)
Japanese (ja)
Inventor
鴻声 蘇
暁山 王
賓 劉
憲 陳
相 李
鹿燕 朱
淑亜 王
双 王
文文 王
霊麗 黄
斉磊 王
海涛 胡
莉莉 張
潔 高
子甲 任
春峰 肖
亜里 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Gensciences Inc
Original Assignee
Zhengzhou Gensciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Gensciences Inc filed Critical Zhengzhou Gensciences Inc
Publication of JP2021530437A publication Critical patent/JP2021530437A/ja
Priority to JP2023069317A priority Critical patent/JP7492780B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020564649A 2018-05-18 2019-05-16 改良されたｆｖｉｉｉ融合タンパク質及びその応用 Pending JP2021530437A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023069317A JP7492780B2 (ja) 2018-05-18 2023-04-20 改良されたｆｖｉｉｉ融合タンパク質及びその応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810481941 2018-05-18
CN201810481941.X 2018-05-18
PCT/CN2019/087156 WO2019219049A1 (zh) 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023069317A Division JP7492780B2 (ja) 2018-05-18 2023-04-20 改良されたｆｖｉｉｉ融合タンパク質及びその応用

Publications (1)

Publication Number Publication Date
JP2021530437A true JP2021530437A (ja) 2021-11-11

Family

ID=68539524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564649A Pending JP2021530437A (ja) 2018-05-18 2019-05-16 改良されたｆｖｉｉｉ融合タンパク質及びその応用
JP2023069317A Active JP7492780B2 (ja) 2018-05-18 2023-04-20 改良されたｆｖｉｉｉ融合タンパク質及びその応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023069317A Active JP7492780B2 (ja) 2018-05-18 2023-04-20 改良されたｆｖｉｉｉ融合タンパク質及びその応用

Country Status (9)

Country Link
US (1) US12440572B2 (enExample)
EP (1) EP3816181A4 (enExample)
JP (2) JP2021530437A (enExample)
KR (1) KR102575788B1 (enExample)
CN (2) CN113039200B (enExample)
BR (1) BR112020023168A2 (enExample)
MA (1) MA53020A (enExample)
MX (1) MX2020012103A (enExample)
WO (1) WO2019219049A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534563A1 (en) 2022-05-25 2025-04-09 Jiangsu Gensciences Inc. Fviii fusion protein conjugate having extended half-life and use thereof
CN116284411B (zh) * 2023-02-03 2024-02-13 北京基科晟斯医药科技有限公司 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510053A (ja) * 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
JP2013519699A (ja) * 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
JP2014531910A (ja) * 2011-10-18 2014-12-04 シーエスエル、リミテッド 再構成後の精製第ｖｉｉｉ因子の安定性を改善するための方法
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
WO2018032637A1 (zh) * 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818679A (en) 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20120121613A1 (en) 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
CN103172745A (zh) 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
EA035323B1 (ru) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
WO2014008480A2 (en) * 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN104519912A (zh) 2012-08-13 2015-04-15 诺和诺德A/S（股份有限公司） 液体因子viii制剂
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
CN103539860B (zh) 2013-11-01 2014-12-03 广州优联康医药科技有限公司 一种长效重组人促卵泡激素融合蛋白
SG11201805497QA (en) * 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510053A (ja) * 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
JP2013519699A (ja) * 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
JP2014531910A (ja) * 2011-10-18 2014-12-04 シーエスエル、リミテッド 再構成後の精製第ｖｉｉｉ因子の安定性を改善するための方法
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
WO2018032637A1 (zh) * 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
CN113039200B (zh) 2023-07-25
MX2020012103A (es) 2021-01-29
KR20210005248A (ko) 2021-01-13
BR112020023168A2 (pt) 2021-02-09
JP2023093634A (ja) 2023-07-04
EP3816181A4 (en) 2022-04-20
CN117467019A (zh) 2024-01-30
MA53020A (fr) 2021-05-05
KR102575788B1 (ko) 2023-09-08
EP3816181A1 (en) 2021-05-05
JP7492780B2 (ja) 2024-05-30
CN113039200A (zh) 2021-06-25
US12440572B2 (en) 2025-10-14
US20210361775A1 (en) 2021-11-25
WO2019219049A1 (zh) 2019-11-21

Similar Documents

Publication Publication Date Title
JP7492780B2 (ja) 改良されたｆｖｉｉｉ融合タンパク質及びその応用
EP2371856B1 (en) Site-directed modification of FVIII
JP5832285B2 (ja) 延長されたインビボ半減期を有する第ｖｉｉｉ因子、フォン・ヴィレブランド因子又はそれらの複合体
ES2657291T3 (es) Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
KR20110017420A (ko) 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
CN112673026A (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
WO2019219048A1 (zh) 具有延长半衰期的融合多肽缀合物
RU2789085C2 (ru) Улучшенный белок слияния fviii и его применение
HK40046100A (en) Improved fviii fusion protein and use thereof
EP4534563A1 (en) Fviii fusion protein conjugate having extended half-life and use thereof
AU2016203693B2 (en) Site-directed modification of FVIII
CN114929261A (zh) 凝血因子viii的皮下施用
HK40079628A (en) Subcutaneous administration of factor viii
AU2012203813B2 (en) Site-directed modification of FVIII
AU2013203348B2 (en) Site-directed modification of FVIII
HK1154047A (en) Fviii muteins for treatment of von willebrand disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221220